Connection

JASON KIMATA to Antibodies, Viral

This is a "connection" page, showing publications JASON KIMATA has written about Antibodies, Viral.
Connection Strength

0.340
  1. Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2. Front Immunol. 2021; 12:693462.
    View in: PubMed
    Score: 0.115
  2. Absence of XMRV in peripheral blood mononuclear cells of ARV-treatment na?ve HIV-1 infected and HIV-1/HCV coinfected individuals and blood donors. PLoS One. 2012; 7(2):e31398.
    View in: PubMed
    Score: 0.059
  3. Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):174-185.
    View in: PubMed
    Score: 0.033
  4. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
    View in: PubMed
    Score: 0.031
  5. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
    View in: PubMed
    Score: 0.030
  6. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.028
  7. The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway. J Virol. 1993 Jun; 67(6):3134-41.
    View in: PubMed
    Score: 0.016
  8. Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses. Virol J. 2008 Aug 04; 5:90.
    View in: PubMed
    Score: 0.012
  9. Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge. J Med Primatol. 2007 Aug; 36(4-5):254-65.
    View in: PubMed
    Score: 0.011
  10. Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol. 1998 Jan; 72(1):209-17.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.